Dynamic Structure-Based Pharmacophore Model Development: A New and Effective Addition in the Histone Deacetylase 8 (HDAC8) Inhibitor Discovery
暂无分享,去创建一个
[1] The role of adenylate cyclase in the D-2 modulation of the release of dopamine: a microdialysis study in the striatum of the rat M. Santiago and B.H.C. Westerink. Centre for Pharmacy, University of Groningen, Groningen, The Netherlands , 1989, Journal of Neuroscience Methods.
[2] T. Darden,et al. A smooth particle mesh Ewald method , 1995 .
[3] S. Schreiber,et al. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. , 1997, Current opinion in chemical biology.
[4] P. Marks,et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.
[5] J. Clark,et al. Cloning and characterization of a novel human histone deacetylase, HDAC8. , 2000, The Biochemical journal.
[6] 上野 京子,et al. プロダクト・レビュー SciFinder Scholar , 2001 .
[7] S. Schreiber,et al. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. , 2001, Organic letters.
[8] C. Allis,et al. Translating the Histone Code , 2001, Science.
[9] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[10] P. Becker,et al. Histone acetylation: a switch between repressive and permissive chromatin , 2002, EMBO reports.
[11] Y. Hofmann,et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. , 2003, Human molecular genetics.
[12] Leslie M Thompson,et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[13] Michael Grunstein,et al. Histone acetylation and deacetylation in yeast , 2003, Nature Reviews Molecular Cell Biology.
[14] Richard D. Taylor,et al. Improved protein–ligand docking using GOLD , 2003, Proteins.
[15] R. De Francesco,et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[16] Sang Gyun Kim,et al. Class I Histone Deacetylase-Selective Novel Synthetic Inhibitors Potently Inhibit Human Tumor Proliferation , 2004, Clinical Cancer Research.
[17] J. R. Somoza,et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. , 2004, Structure.
[18] T. Langer,et al. Pharmacophore definition and 3D searches. , 2004, Drug discovery today. Technologies.
[19] A. W. Schüttelkopf,et al. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.
[20] P. Schultz,et al. Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group. , 2004, Bioorganic & medicinal chemistry letters.
[21] J. Briggs,et al. Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors. , 2005, Journal of medicinal chemistry.
[22] M. Dokmanovic,et al. Prospects: Histone deacetylase inhibitors , 2005, Journal of cellular biochemistry.
[23] R. Ficner,et al. Crystal structure of a bacterial class 2 histone deacetylase homologue. , 2005, Journal of molecular biology.
[24] P. Marks,et al. Histone deacetylase inhibitors: discovery and development as anticancer agents , 2005, Expert opinion on investigational drugs.
[25] K. Bhalla. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] P. Geerlings,et al. Theoretical study revealing the functioning of a novel combination of catalytic motifs in histone deacetylase. , 2005, Bioorganic & medicinal chemistry.
[27] G. Jiang,et al. The molecular mechanism of HDAC inhibitors in anticancer effects. , 2006, Cellular & molecular immunology.
[28] C. Horvath,et al. Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases. , 2006, Bioorganic & medicinal chemistry.
[29] A. Ben Wagner,et al. SciFinder Scholar 2006: An Empirical Analysis of Research Topic Query Processing , 2006, J. Chem. Inf. Model..
[30] Y. Bang,et al. Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.
[31] M. Parrinello,et al. Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.
[32] B. Morrison,et al. Histone deacetylases: Focus on the nervous system , 2007, Cellular and Molecular Life Sciences.
[33] R. De Francesco,et al. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8–substrate complex , 2007, EMBO reports.
[34] Michele Pallaoro,et al. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics , 2007, Cell Research.
[35] Eric Verdin,et al. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.
[36] D. Mottet,et al. Histone deacetylases: target enzymes for cancer therapy , 2007, Clinical & Experimental Metastasis.
[37] Jun Lu,et al. HDAC inhibitors: a potential new category of anti-tumor agents. , 2007, Cellular & molecular immunology.
[38] I. Adcock. HDAC inhibitors as anti‐inflammatory agents , 2007, British journal of pharmacology.
[39] J. Buggy,et al. Interferon-α is able to maintain complete molecular remission induced by imatinib after its discontinuation , 2008, Leukemia.
[40] Jianpeng Ma,et al. Molecular docking study of the interactions between the thioesterase domain of human fatty acid synthase and its ligands , 2008, Proteins.
[41] Carsten Kutzner,et al. GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.
[42] B. Wirth,et al. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders , 2008, Expert opinion on investigational drugs.
[43] C. Fierke,et al. Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors. , 2008, Biochemistry.
[44] Christopher B. Harrison,et al. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. , 2008, Journal of medicinal chemistry.
[45] Keun Woo Lee,et al. Molecular dynamics simulation study of PTP1B with allosteric inhibitor and its application in receptor based pharmacophore modeling , 2008, J. Comput. Aided Mol. Des..
[46] Adriano Martinelli,et al. Docking of Hydroxamic Acids into HDAC1 and HDAC8: A Rationalization of Activity Trends and Selectivities , 2009, J. Chem. Inf. Model..
[47] Zhihai Liu,et al. Evaluation of the performance of four molecular docking programs on a diverse set of protein‐ligand complexes , 2010, J. Comput. Chem..
[48] Sugunadevi Sakkiah,et al. Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery. , 2010, Journal of molecular graphics & modelling.
[49] C. Fierke,et al. Structures of metal-substituted human histone deacetylase 8 provide mechanistic inferences on biological function . , 2010, Biochemistry.
[50] J. Bradner,et al. On the inhibition of histone deacetylase 8. , 2010, Bioorganic & medicinal chemistry.
[51] Evan Bolton,et al. An overview of the PubChem BioAssay resource , 2009, Nucleic Acids Res..
[52] Thangapandian Sundarapandian,et al. Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery , 2010 .
[53] Ruibo Wu,et al. A proton-shuttle reaction mechanism for histone deacetylase 8 and the catalytic role of metal ions. , 2010, Journal of the American Chemical Society.
[54] S. Sakkiah,et al. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design. , 2010, European journal of medicinal chemistry.
[55] Yonghua Wang,et al. Structural Determination of Three Different Series of Compounds as Hsp90 Inhibitors Using 3D-QSAR Modeling, Molecular Docking and Molecular Dynamics Methods , 2011, International journal of molecular sciences.
[56] Dariusz Plewczynski,et al. Can we trust docking results? Evaluation of seven commonly used programs on PDBbind database , 2011, J. Comput. Chem..
[57] T. McKinsey,et al. Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart. , 2011, Journal of molecular and cellular cardiology.
[58] Ruixin Zhu,et al. Novel Natural Inhibitors of CYP1A2 Identified by in Silico and in Vitro Screening , 2011, International journal of molecular sciences.
[59] Hsuan-Cheng Huang,et al. Reviewing Ligand-Based Rational Drug Design: The Search for an ATP Synthase Inhibitor , 2011, International journal of molecular sciences.